Skip to main content

Market Overview

Takeda FY20 Profit Surges, Revenue Drops; Guides For Weak FY21 Profit

Share:
Takeda FY20 Profit Surges, Revenue Drops; Guides For Weak FY21 Profit
  • Takeda Pharmaceutical Co Ltd (NYSE: TAKreported an FY20 net profit of ¥376 billion, a 750% Y/Y increase, reflecting gains on non-core asset sales and lower acquisition-related expenses.
  • Takeda exceeded its $10 billion non-core asset divestiture target and has announced 12 deals since January 2019 to date for a total aggregate value of up to $12.9 billion.
  • Core net income expanded around 9% Y/Y to ¥655.5 billion.
  • Operating profit grew 407.2% Y/Y to ¥509.3 billion, and core operating profit remained unchanged at ¥967.9 billion.
  • Revenue of ¥3.2 trillion fell 2.8% from last year. On an underlying basis, revenue grew 2.2%, driven by the growth of Takeda's 14 global brands, up 16% Y/Y.
  • The company's five key business areas — Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience — with ¥2.6 trillion reported revenue delivered Y/Y underlying revenue growth of 4.7%.
  • At an underlying core operating profit margin of 30.2%, the company is also deleveraging, with a net debt/adjusted EBITDA ratio of 3.2x at the end of Q4, down from 3.8x in March 2020. Takeda is on course to meet its medium-term deleveraging goal of 2x within FY2021-FY2023.
  • Operating cash flow increased by 50.9% to ¥1 trillion. Free cash flow ¥1.2 trillion representing an increase of 27.9% Y/Y.
  • Guidance: For FY21, the company projects a net profit of ¥250 billion, core EPS of ¥394, operating profit of ¥488 billion, and core operating profit of ¥930 billion, all lower than FY20.
  • However, revenue for the year is expected to be ¥3.4 trillion, +5.4% than last year.
  • Takeda expects underlying revenue growth to accelerate to "mid-single-digit." Underlying core operating profit and underlying core EPS are expected to also grow at "mid-single-digit."
  • Tt anticipates up to six regulatory submissions by year-end FY2021, with the potential for four approvals.
  • Price Action: TAK shares closed 0.5% higher at $16.96 on Monday.
 

Related Articles (TKPHF + TAK)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Earnings News Guidance Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com